Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Practice guidelines for lipid-based amphotericin B in stem cell transplantrecipients
Autore:
Quilitz, RE; Arnold, AD; Briones, GR; Dix, SP; Ippoliti, C; Kennedy, LD; Lucich, JL; Mehta, J; Peters, BG; Tice, DS;
Indirizzi:
H Lee Moffitt Canc Ctr, Dept Pharm, Tampa, FL 33612 USA H Lee Moffitt CancCtr Tampa FL USA 33612 Dept Pharm, Tampa, FL 33612 USA Childrens Hosp, Dept Pharm, Boston, MA USA Childrens Hosp Boston MA USAChildrens Hosp, Dept Pharm, Boston, MA USA Childrens Hosp Orange Cty, Orange, CA 92668 USA Childrens Hosp Orange CtyOrange CA USA 92668 e Cty, Orange, CA 92668 USA St Lukes Hosp, Oncol Hematol Associates Kansas City, Kansas City, MO USA St Lukes Hosp Kansas City MO USA ciates Kansas City, Kansas City, MO USA Univ Texas, MD Anderson Canc Ctr, Dept Pharm, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 nc Ctr, Dept Pharm, Houston, TX 77030 USA Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC USA Wake Forest UnivWinston Salem NC USA ist Med Ctr, Winston Salem, NC USA Northwestern Univ, Boston, MA USA Northwestern Univ Boston MA USANorthwestern Univ, Boston, MA USA S Carolina Canc Ctr, Div Transplantat Med, Columbia, SC USA S Carolina Canc Ctr Columbia SC USA v Transplantat Med, Columbia, SC USA S Carolina Canc Ctr, Myeloma & Lymphoma Program, Columbia, SC USA S Carolina Canc Ctr Columbia SC USA & Lymphoma Program, Columbia, SC USA St Louis Univ, Hlth Sci Ctr, St Louis, MO 63103 USA St Louis Univ St Louis MO USA 63103 Hlth Sci Ctr, St Louis, MO 63103 USA Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA Thomas Jefferson Univ Hosp Philadelphia PA USA 19107 elphia, PA 19107 USA
Titolo Testata:
ANNALS OF PHARMACOTHERAPY
fascicolo: 2, volume: 35, anno: 2001,
pagine: 206 - 216
SICI:
1060-0280(200102)35:2<206:PGFLAB>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
INVASIVE FUNGAL-INFECTIONS; NEUTROPENIC PATIENTS; COLLOIDAL DISPERSION; MARROW TRANSPLANT; CRYPTOCOCCAL MENINGITIS; IMMUNOCOMPROMISED PATIENTS; HEPATOSPLENIC CANDIDIASIS; ASPERGILLUS INFECTIONS; LIPOSOMAL FORMULATION; TISSUE DISTRIBUTION;
Keywords:
amphotericin B; Aspergillus; bone marrow transplant; fungal infection; lipid;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
51
Recensione:
Indirizzi per estratti:
Indirizzo: Quilitz, RE H Lee Moffitt Canc Ctr, Dept Pharm, 12902 Magnolia Dr, Tampa, FL 33612 USA H Lee Moffitt Canc Ctr 12902 Magnolia Dr Tampa FL USA 33612 SA
Citazione:
R.E. Quilitz et al., "Practice guidelines for lipid-based amphotericin B in stem cell transplantrecipients", ANN PHARMAC, 35(2), 2001, pp. 206-216

Abstract

OBJECTIVE: To provide clinicians who practice in the stem cell transplantation (SCT) setting with practical guidelines for the use of lipid-based amphotericin B (AmB) formulations in SCT patients who have documented or probable invasive fungal infections, are experiencing neutropenic fever, or require secondary prophylaxis for fungal infections. DATA SOURCES: Recommendations are based on the results of a two-day consensus meeting that convened clinicians versed in the management of infectiouscomplications in patients undergoing SCT. This meeting, which was held October 21-23, 1998, in Orlando, Florida, was sponsored by an educational grant from The Liposome Company. In addition, primary articles were identified by MEDLINE search (1980-December 1999) and through secondary sources. STUDY SELECTION AND DATA EXTRACTION: All Of the articles identified from the data sources were evaluated, and all information deemed relevant was included in this review. DATA SYNTHESIS: Immunocompromised patients, particularly patients undergoing high-dose chemotherapy with SCT, experience a high degree of morbidity and mortality from invasive fungal infections. Historically, treatment for such infections with conventional AmB had been limited primarily by its associated nephrotoxicity. Lipid-based formulations of AmB have helped to advance the management of invasive fungal infections in the SCT population by offering a treatment alternative that allows for administration of amounts ofactive drug to produce clinical and mycologic responses, compared with conventional AmB, in a delivery system that is less nephrotoxic. Unfortunatelythese agents are relatively expensive. Therefore, patients who are candidates for lipid-based products must be selected carefully. CONCLUSIONS: Practical guidelines-are provided for the use of lipid-based AmB formulations in SCT patients who have documented or probable invasive fungal infections, are experiencing neutropenic fever, or require secondary prophylaxis for fungal infections.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/10/20 alle ore 22:04:40